RAMP1
ENSG00000132329
Target class
Other membrane protein
Chromosome
2
Approved drugs
2
Clinical candidates (approved and in development)
3
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- RAMP1
- Gene name
- Receptor activity modifying protein 1
- Gene symbol
- RAMP1
- Protein name
- Receptor activity-modifying protein 1 (Calcitonin-receptor-like receptor activity-modifying protein 1) (CRLR activity-modifying protein 1)
- Gene biotype
- Protein coding
- Gene family
- Receptor (G protein-coupled) activity modifying proteins
- Target class
- Other membrane protein
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 901.83
- Tissue specificity (Gini)
- 0.622
- Tissue specificity (tau)
- 0.878
- KEGG gene identifiers
- hsa:10267
- Protein interaction confidence
- 0.880053
- Protein interaction partners
- 19
- R-HSA-418555
- R-HSA-419812
- End position
- 237912111
- Start position
- 237858893
- Chromosome
- 2
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein .
- Nuclear membrane
- Nucleoplasm
Publication evidence
- PubMed 33602864
- Tissue specificity (tau)
- 0.877936
- Expression inequality (Gini)
- 0.621741
Expression in transcripts per million
- Uterus
- 901.83
- Artery - Aorta
- 595.93
- Cervix - Endocervix
- 546.83
- Cervix - Ectocervix
- 463
- Colon - Sigmoid
- 389.46
Expression in transcripts per million
- Uterus901.83
- Artery - Aorta595.93
- Cervix - Endocervix546.83
- Cervix - Ectocervix463
- Colon - Sigmoid389.46
- Fallopian Tube360.41
- Artery - Coronary300.12
- Artery - Tibial282.86
- Esophagus - Gastroesophageal Junction255.43
- Bladder224.44
- Esophagus - Muscularis217.45
- Prostate156.83
- Brain - Nucleus accumbens (basal ganglia)126.21
- Heart - Left Ventricle103.01
- Heart - Atrial Appendage101.08
- Colon - Transverse97.89
- Brain - Amygdala95.33
- Brain - Anterior cingulate cortex (BA24)93.78
- Brain - Caudate (basal ganglia)93.05
- Muscle - Skeletal91.23
- Brain - Frontal Cortex (BA9)89.43
- Brain - Cortex88.62
- Brain - Hippocampus87.99
- Brain - Substantia nigra85.99
- Brain - Hypothalamus84.36
And 29 more, listed on the interactive page.
- GO:0001525
- GO:0006816
- GO:0007189
- GO:0010560
- GO:0015031
- GO:0031623
- GO:0072659
- GO:0097647
- GO:0150059
- GO:1990408
- GO:0005886
- GO:0009986
- GO:0043235
- GO:1990406
- GO:0001635
- GO:0005515
- GO:0015026
- GO:0097643
- GO:1990407
Related records
Trials (281)
- 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
- A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- A Controlled Trial of Erenumab in Migraine Prevention
- A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
- A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
- A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
- A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes
- A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes
- A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
- A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
- A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
- A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
- A Prospective Real World Study of Rimegepant in the Treatment of Migraine
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
- A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study
- A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
- A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
- A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women
- A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
Drugs (16)
- Adrenomedullin
- Atogepant
- Calcitonin
- Calcitonin human
- Calcitonin salmon
- Davalintide Amylin receptor AMY1, CALCR/RAMP1 agonist
- Davalintide acetate Amylin receptor AMY1, CALCR/RAMP1 agonist
- Erenumab
- HTL-0022562
- Olcegepant
- Pramlintide Amylin receptor AMY1, CALCR/RAMP1 agonist
- Pramlintide acetate Amylin receptor AMY1, CALCR/RAMP1 agonist
- Rimegepant
- Telcagepant
- Ubrogepant
- Zavegepant Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist